<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3010222844
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Surlex 200 mg  / 2 ml
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SUGAMMADEX
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2033.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DR. REDDY" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DR. REDDY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2272]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        V03AB35
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Surlex contains the active substance Sugammadex. Surlex is considered to be a Selective Relaxant Binding Agent since it only works with specific muscle relaxants, rocuronium bromide or vecuronium bromide.</p><p><strong>What Surlex is used for</strong></p><p>When you have some types of operations, your muscles must be completely relaxed. This makes it easier for the surgeon to do the operation. For this, the general anaesthetic you are given includes medicines to make your muscles relax. These are called muscle relaxants, and examples include rocuronium bromide and vecuronium bromide. Because these medicines also make your breathing muscles relax, you need help to breathe (artificial ventilation) during and after your operation until you can breathe on your own again.</p><p>Surlex is used to speed up the recovery of your muscles after an operation to allow you to breathe on your own again earlier. It does this by combining with the rocuronium bromide or vecuronium bromide in your body. It can be used in adults whenever rocuronium bromide or vecuronium bromide is used and in children and adolescents (aged 2 to 17 years) when rocuronium bromide is used for a moderate level of relaxation.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You should not be given Surlex</p><p>&bull; if you are allergic to Sugammadex or any of the other ingredients of this medicine (listed in section 6).</p><p>&rarr; Tell your anaesthetist if this applies to you.</p><p><strong>Warnings and precautions</strong></p><p>Talk to your anaesthetist before Surlex is given</p><p>&bull; if you have kidney disease or had in the past. This is important as Surlex is removed from your body by the kidneys.</p><p>&bull; if you have liver disease or have had it in the past.</p><p>&bull; if you have fluid retention (oedema).</p><p>&bull; if you have diseases which are known to give an increased risk of bleeding (disturbances of blood clotting) or anticoagulation medication.</p><p><strong>Children and adolescents</strong></p><p>This medicine is not recommended for infants less than 2 years of age.</p><p><strong>Other medicines and Surlex</strong></p><p>&rarr; Tell your anaesthetist if you are taking, have recently taken or might take any other medicines.</p><p>Surlex may affect other medicines or be affected by them.</p><p><strong>Some medicines reduce the effect of Surlex</strong></p><p>&rarr; It is especially important that you tell your anaesthetist if you have recently taken:</p><p>&bull; toremifene (used to treat breast cancer).</p><p>&bull; fusidic acid (an antibiotic).</p><p><strong>Surlex can affect hormonal contraceptives</strong></p><p>&bull; Surlex can make hormonal contraceptives - including the &lsquo;Pill&rsquo;, vaginal ring, implants or a hormonal IntraUterine System (IUS) - less effective because it reduces how much you get of the progestogen hormone. The amount of progestogen lost by using Surlex is about the same as missing one oral contraceptive Pill.</p><p>&rarr; If you are taking the Pill on the same day as Surlex is given to you, follow the instructions for a missed dose in the Pill&rsquo;s package leaflet.</p><p>&rarr; If you are using other hormonal contraceptives (for example a vaginal ring, implant or IUS) you should use an additional non-hormonal contraceptive method (such as a condom) for the next 7 days and follow the advice in the package leaflet.</p><p><strong>Effects on blood tests</strong></p><p>In general, Surlex does not have an effect on laboratory tests. However, it may affect the results of a blood test for a hormone called progesterone. Talk to your doctor if your progesterone levels need to be tested on the same day you receive Surlex.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>&rarr; Tell your anaesthetist if you are pregnant or might be pregnant or if you are breast-feeding.</p><p>You may still be given Surlex, but you need to discuss it first.</p><p>It is not known whether sugammadex can pass into breast milk. Your anaesthetist will help you decide whether to stop breast-feeding, or whether to abstain from sugammadex therapy, considering the benefit of breast-feeding to the baby and the benefit of Surlex to the mother.</p><p><strong>Driving and using machines</strong></p><p>Surlex has no known influence on your ability to drive and use machines.</p><p><strong>Surlex contains sodium </strong></p><p>This medicine contains up to 9.7 mg sodium (main component of cooking / table salt) in each mL. This is equivalent to 0.5 % of the recommended maximum daily dietary intake of sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Surlex will be given to you by your anaesthetist, or under the care of your anaesthetist.</p><p><strong>The dose</strong></p><p>Your anaesthetist will work out the dose of Surlex you need based on:</p><p>&bull; your weight</p><p>&bull; how much the muscle relaxant medicine is still affecting you.</p><p>The usual dose is 2-4 mg per kg body weight. A dose of 16 mg/kg can be used in adults if urgent recovery from muscle relaxation is needed.</p><p>The dose of Surlex for children is 2 mg/kg (children and adolescents between 2-17 years old).</p><p><strong>How Surlex is given</strong></p><p>Surlex will be given to you by your anaesthetist. It is given as a single injection through an intravenous line.</p><p><strong>If more Surlex is given to you than recommended</strong></p><p>As your anaesthetist will be monitoring your condition carefully, it is unlikely that you will be given too much Surlex. But even if this happens, it is unlikely to cause any problems.</p><p>If you have any further questions on the use of this medicine, ask your anaesthetist or other doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>If these side effects occur while you are under anaesthesia, they will be seen and treated by your anaesthetist.</p><p><strong>Common side effects (may affect up to 1 in 10 people)</strong></p><p>&bull; Cough</p><p>&bull; Airway difficulties that may include coughing or moving as if you are waking or taking a breath</p><p>&bull; Light anaesthesia - you may start to come out of deep sleep, so need more anaesthesia. This might cause you to move or cough at the end of the operation</p><p>&bull; Complications during your procedure such as changes in heart rate, coughing or moving</p><p>&bull; Decreased blood pressure due to the surgical procedure</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people)</strong></p><p>&bull; Shortness of breath due to muscle cramps of the airways (bronchospasm) occurred in patients with a history of lung problems</p><p>&bull; Allergic (drug hypersensitivity) reactions - such as a rash, red skin, swelling of your tongue and/or throat, shortness of breath, changes in blood pressure or heart rate, sometimes resulting in a serious decrease of blood pressure. Severe allergic or allergic-like reactions can be life threatening.</p><p>Allergic reactions were reported more commonly in healthy, conscious volunteers</p><p>&bull; Return of muscle relaxation after the operation</p><p><strong>Frequency not known</strong></p><p>&bull; Severe slowing of the heart and slowing of the heart up to cardiac arrest may occur when</p><p>Surlex is administered</p><p><strong>Reporting of side effects</strong></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your &lt;doctor, health care provider&gt; &lt;or&gt; &lt;pharmacist&gt;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Storage will be handled by healthcare professionals.</p><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and on the label after &lsquo;EXP&rsquo;. The expiry date refers to the last day of that month.</p><p>Do not store Above 30 &deg;C. Do not freeze. Keep the vial in the outer carton in order to protect from light.After first opening and dilution, store at 2 to 8&deg;C and use within 24 hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is <strong>sugammadex</strong>.</p><p>The other ingredients are water for injections, hydrochloric acid, sodium hydroxide and Nitrogen</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Sugammadex injection 200 mg/2 mL (100 mg/mL) is packed in 2 mL Type I tubular glass vial with rubber stopper and flip off seal.
Sugammadex injection 500 mg/5 mL (100 mg/mL) is packed in 5 mL Type I tubular glass vial with rubber stopper and flip off seal.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>MARKETING AUTHORIZATION HOLDER: </strong></p><p>Sudair Pharma Company (SPC)</p><p>King Fahad road, Building 8006- 4th Floor Riyadh, Saudi Arabia</p><p>Tel: +966-11-920001432</p><p>Fax: +966-11-4668195</p><p>Email: info@sudairpharma.com</p><p>Mailing: P.O. Box 12363 Riyadh, Saudi Arabia</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>Dr Reddys Laboratories Ltd , FTO 9</p><p>Plot No. Q1 to Q5, Phase - III, VSEZ,</p><p>Visakhapatnam District ,</p><p>Andhra Pradesh, 530 046, Duvvada,</p><p>INDIA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 10/2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي دواء سورلكس على المادة الفعالة سوجاماداكس. تعتبر مادة سوجاماداكس من مرخيات العضلات الانتقائية حيث أنها تعمل فقط مع بعض مرخيات العضلات : روكورونيوم برومايد أو فيكورونيوم برومايد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ما هي دواعي استعمال دواء سورلكس ؟</strong></p><p dir="RTL">ينبغي إرخاء العضلات بشكل كامل إذا كنت ستخضع لإجراء أي عملية جراحية. حيث يُسهل ذلك على أخصائي الجراحة إجراء العملية الجراحية. لذا، تحتوي أدوية التخدير العام، التي يتم إعطائها لك، على أدوية أخرى تعمل على إرخاء العضلات. لذا، فإنها تُسمي بمرخيات العضلات، وتشمل على سبيل المثال: روكورونيوم برومايد وفيكورونيوم برومايد حيث تعمل هذه الأدوية أيضًا على إرخاء عضلات الجهاز التنفسى، ويلزم ذلك توافر أدوات وأجهزة تساعدك على التنفس (التنفس الاصطناعي) خلال وبعد إجراء العملية الجراحية حتي تتمكن من استعادة القدرة على التنفس مرة أخرى بمفردك.</p><p dir="RTL">يستخدم دواء سورلكس لتعزيز استعادة الحركة الطبيعية للعضلات سريعًا عقب إجراء العملية الجراحية، حتي تتمكن من استعادة القدرة على التنفس مرة أخرى بمفردك. يتم ذلك عن طريق تفاعل هذا الدواء مع روكورونيوم بروميد وفيكورونيوم برومايد داخل الجسم لديك. يُستخدم في المرضي من البالغين فى حالة استخدام روكورونيوم برومايد أو فيكورونيوم برومايد كَمُرخيات للعضلات، كما يُستخدم في المرضي من الأطفال والمراهقين ( الذين تتراوح أعمارهم&nbsp; من 2 إلى 17 عامًا)، في حال استخدام روكورونيوم بروميد للحصول على مستوى متوسط من ارخاء العضلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحظر استخدام دواء سورلكس في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه سوجاماداكس أو تجاه أي مكون من المكونات الأخرى الداخلة في تركيب هذا الدَّواء (المدرجة في القسم رقم 6).&nbsp;&nbsp;</p><p dir="RTL">&larr; إذا انطبق عليك أيًا مما سبق فأخبر طبيب التخدير الخاص بك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تحذيرات واحتياطات:</strong></p><p dir="RTL">أخبر طبيب التخدير الخاص بك قبل استخدام دواء سورلكس في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني أو عانيت مسبقًا من أمراض بالكلى. فهذا مهم للغاية حيت أنه يتم التخلص من دواء سورلكس من الجسم من خلال الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أو قد عانيت مسبقاً من أمراض بالكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من احتباس السوائل بالجسم (الاستسقاء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أمراض تزيد من خطر التعرض لحدوث النزيف (اضطرابات بتجلط الدم) أو تستخدم أيه أدوية مضادة لتجلط الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام في المرضى من الأطفال والمراهقين</strong></p><p dir="RTL">لا يُوصي باستخدام هذا الدواء في المرضى من الأطفال الرضع الذين تقل أعمارهم عن عامين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام دواء سورلكس مع أدوية أخرى </strong></p><p dir="RTL">&larr; إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى فأخبر طبيب التخدير الخاص بك.</p><p dir="RTL">حيث قد يُؤثر أو يتأثر دواء سورلكس بالأدوية الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تقلل بعض الأدوية من فعالية دواء سورلكس .</strong></p><p dir="RTL">ولذلك من المهم إبلاغ طبيب التخدير الخاص بك إذا كنت تناولت مؤخراً أي من الأدوية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توريميفين (دواء يستخدم لعلاج سرطان الثدي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمض الفيوسيديك (مضاد حيوي).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>يمكن أن يؤثر دواء سورلكس على فعالية وسائل منع الحمل الهرمونية</strong></p><p dir="RTL">يُقلل دواء سورلكس من فعالية أدوية منع الحمل الهرمونية &ndash; بما في ذلك &quot;حبوب منع الحمل&quot; أو الحلقات المهبلية أو الكبسولات المزروعة تحت الجلد أو أجهزة اللولب الرحمي الهرموني &nbsp;(IUS)- لأنه يعمل على تقليل تركيز هرمون البروجستوجن المُفرز من وسائل منع الحمل في الجسم. يُعد النقص في تركيز هرمون البروجستوجن، المُفرز من وسائل منع الحمل في الجسم، والناتج عن استخدام دواء &nbsp;سورلكس مكافئ تقريبًا لنسيان أوعدم تناول جرعة واحدة من حبوب&nbsp; منع الحمل الفموية.</p><p dir="RTL">&larr; ينبغي عليكِ إتباع التعليمات الخاصة بالجرعة المنسية في النشرة المُرفقة بعبوة حبوب منع الحمل، إذا كنت تتناولين حبوب منع الحمل في نفس يوم استخدام دواء سورلكس .</p><p dir="RTL">&larr; إذا كنتِ تستخدمين وسائل منع حمل هرمونية أخرى (على سبيل المثال: الحلقة المهبلية أو الكبسولات المزروعة تحت الجلد أو أجهزة اللولب الرحمي الهرموني)، فينبغي عليكِ خلال الأيام السبع التالية استخدام وسيلة أخرى غير هرمونية لمنع حدوث حمل (مثل الواقي الذكري) وإتباع النصائح الواردة في نشرة العبوة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التَّأثيرات على فحوصات الدَّم:</strong></p><p dir="RTL">لا يؤثر دواء سورلكس ، بصفة عامة، على نتائج الفحوصات المعملية. ومع ذلك، فأنه قد يؤثر على نتائج فحص هرمون البروجسترون في الدم. أخبر الطبيب المعالج لك إذا كنت بحاجة إلى فحص تركيز هرمون البروجسترون في نفس يوم استخدام دواء سورلكس .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">&larr; إذا كنتِ حاملًا، أو تعتقدين أنكِ قد تكونين حاملًا، أو تمارسين الرضاعة الطبيعية، فيُرجى إبلاغ طبيب التخدير الخاص بك.</p><p dir="RTL">قد تستمرين في استخدام دواء سورلكس ، ولكن ينبغي عليكِ مناقشة ذلك أولاً مع الطبيب المعالج لكِ.</p><p dir="RTL">من غير المعروف ما إذا كان دواء سورلكس يُفرز في لبن الأم أم لا. سيساعدك طبيب التخدير الخاص بك في تحديد ما إذا كان ينبغي عليكِ إيقاف ممارسة الرضاعة الطبيعية، أم التوقف عن استخدام دواء سورلكس مع الوضع في الاعتبار فائدة الرضاعة الطبيعية للطفل الرضيع، وأهمية دواء سورلكس للأم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>قيادة السيارات واستخدام الآلات:</strong></p><p dir="RTL">لا يوجد تأثير معروف لدَّواء سورلكس في القدرة على قيادة السيارات واستخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي دواء </strong>&nbsp;<strong>سورلكس على الصوديوم:</strong></p><p dir="RTL">يحتوي هذا الدواء على 9.7 مجم من الصوديوم (مكون رئيسي لملح الطعام) بكل مل. وهذا التركيز يُعادل 0.5% من الحد الأقصى المُوصي باستخدامه يوميًا من الصوديوم في النظام الغذائي الخاص بالأشخاص البالغين.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتم إعطائك دواء سورلكس من قِبَل طبيب التخدير الخاص بك أو تحت إشراف طبيب التخدير الخاص بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الموصي بها:</strong></p><p dir="RTL">سيُحدد طبيب التخدير الخاص بك الجرعة المناسبة لك بناءً على:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وزن الجسم لديك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مدى استمرار مفعول الدواء الذي يُسبب إرخاء العضلات لديك.</p><p dir="RTL">الجرعة المعتادة هي 2-4 مجم لكل كيلوجرام من وزن الجسم. يمكن استخدام جرعة تصل إلى 16مجم/كجم في المرضي من البالغين إذا كانت هناك حاجة إلى التعافي بسرعة من ارتخاء العضلات.</p><p dir="RTL">الجرعة الموصي باستخدامها في المرضي من الأطفال هي 2 مجم/كجم ( في المرضي من الأطفال والمراهقين الذين تتراوح أعمارهم من 2 إلى 17 عام).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>كيفية إعطاء دواء سورلكس </strong></p><p dir="RTL">سيتم إعطائك دواء سورلكس من قِبَل طبيب التخدير الخاص بك. يتم إعطاؤها كجرعة أحادية من خلال الحقن داخل الوريد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تم إعطاءك جرعة أكثر من الجرعة الموصي باستخدامها من دواء سورلكس :</strong></p><p dir="RTL">من غير المُرجح أن يتم إعطاؤك جرعة كبيرة من دواء سورلكس ، نظرًا لأن طبيب التخدير الخاص بك سيتابع حالتك الصحية بعناية. ولكن حتى إذا حدث هذا، فمن غير المُرجح أن يتسبب ذلك في حدوث أية أضرار.</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدواء، فاستشر طبيب التخدير الخاص بك أو الطبيب المعالج لك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يُسبب هذا الدَّواء، مثله مثل كافة الأدوية، آثارًا جانبية على الرَّغم من عدم حدوثها لجميع المرضى.</p><p dir="RTL">إذا حدثت هذه الآثار الجانبية أثناء وجودك تحت تأثير التخدير، فسوف يلاحظها طبيب التخدير الخاص بك ويعالجها فورًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل 10&nbsp;مرضى)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات في الشعب الهوائية (مجرى التنفس) والتي قد تشمل سعال أو حركة كما لو كنت مستيقظًا أو تأخذ نفسًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تخدير بسيط، &nbsp;قد تبدأ في الإفاقة من نوم عميق، لذلك قد تحتاج إلى المزيد من التخدير. قد يتسبب ذلك في حدوث حركة أو سعال في نهاية العملية الجراحية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث مضاعفات أثناء إجراء العملية مثل: تغيرات في معدل ضربات القلب أو سعال أو حركة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يتسبب الخضوع للعملية الجراحية في انخفاض ضغط الدم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أثار جانبية غير شائعة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل 100 مريض) </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس بسبب تقلصات عضلية في الشعب الهوائية (تشنج قصبي)، حدث هذا في المرضى الذين لديهم تاريخ مرضي بمشاكل الرئة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية (فرط الحساسية تجاه الأدوية) - مثل حدوث طفح جلدي، احمرار الجلد، انتفاخ اللسان و/أو الحلق،ضيق التنفس، تغيرات في ضغط الدم أو معدل ضربات القلب، مما يؤدي في بعض الأحيان إلى انخفاض حاد خطير في ضغط الدم. حساسية حادة أو تفاعلات تشبه أعراض الحساسية التي قد تكون مهددة للحياة.</p><p dir="RTL">&nbsp;تم الإبلاغ عن الإصابة بحالات تفاعلات حساسية بشكل أكثر شيوعًا في المتطوعين الأصحاء الذين كانوا في حالة وعي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بارتخاء العضلات مرة أخرى بعد الخضوع لإجراء عملية جراحية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>آثار جانبية غير معروف معدل تكرارها</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;بطء شديد في معدل ضربات القلب، بطء في ضربات القلب قد يصل إلى الإصابة &nbsp;بسكتة قلبية عند استخدام دواء سورلكس .</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إن كان لديك أعراض جانبية أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، فضلًا ابلغ &lt;الطبيب&gt; &lt;أو&gt; &lt;مقدم الرعاية الصحية&gt; &lt;أو&gt; &lt;الصيدلي&gt;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيتم حفظ الدواء والتعامل معه من قبل المتخصصين في الرعاية الصحية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ هذا الدَّواء بعيدًا عن رؤية ومتناول الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجنب استخدام هذا الدَّواء بعد انتهاء تاريخ الصلاحية المدون على العبوة والملصق بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يحفظ في درجة حرارة أعلى من 30 درجة مئوية، ولا تعرضه للتجميد. تحفظ الزجاجة داخل العبوة الكرتونية الخارجية لحمايتها من التعرّض للضوء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد فتح العبوة وتخفيفها لأول مرة، يُحفظ في درجة حرارة تتراوح من 2 إلى 8 درجات مئوية ويستخدم خلال 24 ساعة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المادة الفعالة هي:</strong> <strong>سوجاماداكس</strong></p><p dir="RTL">المكونات الأخرى هي ماء مُعد للحقن وحمض هيدروكلوريك وهيدروكسيد الصوديوم ونيتروجين</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتم تعبئة سوجاماداكس 200 مجم / 2 مل (100 مجم / مل) حقن في عبوة زجاجية أنبوبية من النوع الأول بسعة 2 مل بالإضافة إلى سدادة مطاطية ومُحكمة الإغلاق بغطاء قابل للنزع.</p><p dir="RTL">يتم تعبئة حقن سوجاماداكس 500 مجم / 5 مل (100 مجم / مل) حقن في عبوة زجاجية أنبوبية من النوع الأول بسعة 5 مل بالإضافة إلى سدادة مطاطية ومُحكمة الإغلاق بغطاء قابل للنزع.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;الشركة مالكة حق التصريح بالتسويق: </strong></p><p dir="RTL">شركة سدير فارما (SPC)</p><p dir="RTL">طريق الملك فهد، مبنى 8006 - الدور الرابع، الرياض، المملكة العربية السعودية</p><p dir="RTL">هاتف: 920001432-11-966+</p><p dir="RTL">فاكس: 4668195-11-966+</p><p dir="RTL">البريد الإلكتروني: <u>info@sudairpharma.com</u></p><p dir="RTL">عنوان المراسلة: صندوق بريد رقم: 12363، الرياض، المملكة العربية السعودية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة:</strong></p><p dir="RTL">دكتور/ ريدي لابروتيرز، ليمتد، أف تي أو 9</p><p dir="RTL">قطعة أرض من رقم كيو 1 إلى كيو 5، المرحلة الثالثة، منطقة فيساخاباتنام الاقتصادية الخاصة</p><p dir="RTL">حي فيساخاباتنام،</p><p dir="RTL">ولاية أندرا براديش، رقم الحي- 530046، دوفادا</p><p dir="RTL">الهند.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة في 10/2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Surlex 100 mg/ml Solution for Injection.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sugammadex: 100 mg
Hydrochloric Acid: q.s to ph 7.0 to 8.0 
Sodium Hydroxide: q.s to ph 7.0 to 8.0 
Water for Injection q.s to 1 ml.
Nitrogen q.s
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.</p><p>For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Sugammadex should only be administered by, or under the supervision of an anaesthetist.</p><p>The use of an appropriate neuromuscular monitoring technique is recommended to monitor the recovery of neuromuscular blockade.</p><p>The recommended dose of sugammadex depends on the level of neuromuscular blockade to be reversed.</p><p>The recommended dose does not depend on the anaesthetic regimen.</p><p>Sugammadex can be used to reverse different levels of rocuronium or vecuronium induced neuromuscular blockade:</p><p><em>Adults</em></p><p><u>Routine reversal:</u></p><p>A dose of 4 mg/kg sugammadex is recommended if recovery has reached at least 1-2 post-tetanic counts (PTC) following rocuronium or vecuronium induced blockade. Median time to recovery of the T4/T1 ratio to 0.9 is around 3 minutes</p><p>A dose of 2 mg/kg sugammadex is recommended, if spontaneous recovery has occurred up to at least the reappearance of T2 following rocuronium or vecuronium induced blockade. Median time to recovery of the T4/T1 ratio to 0.9 is around 2 minutes.</p><p>Using the recommended doses for routine reversal will result in a slightly faster median time to recovery of the T4/T1 ratio to 0.9 of rocuronium when compared to vecuronium induced neuromuscular blockade.</p><p><u>Immediate reversal of rocuronium-induced blockade:</u></p><p>&nbsp;</p><p>If there is a clinical need for immediate reversal following administration of rocuronium a dose of 16 mg/kg sugammadex is recommended. When 16 mg/kg sugammadex is administered 3 minutes after a bolus dose of 1.2 mg/kg rocuronium bromide, a median time to recovery of the T4/T1 ratio to 0.9 of approximately 1.5 minutes can be expected.</p><p>There is no data to recommend the use of sugammadex for immediate reversal following vecuronium induced blockade.</p><p><u>Re-administration of sugammadex:</u></p><p>In the exceptional situation of recurrence of neuromuscular blockade post-operatively after an initial dose of 2 mg/kg or 4 mg/kg sugammadex, a repeat dose of 4 mg/kg sugammadex is recommended. Following a second dose of sugammadex, the patient should be closely monitored to ascertain sustained return of neuromuscular function.</p><p><u>Re-administration of rocuronium or vecuronium after sugammadex:</u></p><p>For waiting times for re-administration of rocuronium or vecuronium after reversal with sugammadex, see section warnings and precautions.</p><p><em>Additional information on special population</em></p><p><u>Renal impairment:</u></p><p>The use of sugammadex in patients with severe renal impairment (including patients requiring dialysis (CrCl &lt; 30 mL/min)) is not recommended.</p><p>Studies in patients with severe renal impairment do not provide sufficient safety information to support the use of sugammadex in these patients.</p><p>For mild and moderate renal impairment (creatinine clearance &ge; 30 and &lt; 80 mL/min): the dose recommendations are the same as for adults without renal impairment.</p><p><u>Elderly patients:</u></p><p>After administration of sugammadex at reappearance of T2 following a rocuronium induced blockade, the median time to recovery of the T4/T1 ratio to 0.9 in adults (18-64 years) was 2.2 minutes, in elderly adults (65-74 years) it was 2.6 minutes and in very elderly adults (75 years or more) it was 3.6 minutes. Even though the recovery times in elderly tend to be slower, the same dose recommendation as for adults should be followed.</p><p><u>Obese patients:</u></p><p>In obese patients, including morbidly obese patients (body mass index &ge; 40 kg/m<sup>2</sup>), the dose of sugammadex should be based on actual body weight. The same dose recommendations as for adults should be followed.</p><p><u>Hepatic impairment:</u></p><p>Studies in patients with hepatic impairment have not been conducted. Caution should be exercised when considering the use of sugammadex in patients with severe hepatic impairment or when hepatic impairment is accompanied by coagulopathy.</p><p>For mild to moderate hepatic impairment: as sugammadex is mainly excreted renally no dose adjustments are required.</p><p><em>Paediatric population</em></p><p>The data for the paediatric population are limited (one study only for reversal of rocuronium induced blockade at reappearance of T2).</p><p><u>Children and adolescents:</u></p><p>&nbsp;</p><p>For <strong>routine </strong>reversal of rocuronium induced blockade at reappearance of T2 in children and adolescents (2-17 years) 2 mg/kg sugammadex is recommended.</p><p>Sugammadex 100 mg/mL may be diluted to 10 mg/mL to increase the accuracy of dosing in the paediatric population.</p><p>Other routine reversal situations have not been investigated and are therefore not recommended until further data become available.</p><p><strong>Immediate </strong>reversal in children and adolescents has not been investigated and is therefore not recommended until further data become available.</p><p><u>Term newborn infants and infants:</u></p><p>There is only limited experience with the use of sugammadex in infants (30 days to 2 years), and term newborn infants (less than 30 days) have not been studied. The use of sugammadex in term newborn infants and infants is therefore not recommended until further data become available.</p><p><u>Method of administration</u></p><p>Sugammadex should be administered intravenously as a single bolus injection. The bolus injection should be given rapidly, within 10 seconds, into an existing intravenous line. Sugammadex has only been administered as a single bolus injection in clinical trials.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As is normal post-anaesthetic practice following neuromuscular blockade, it is recommended to monitor the patient in the immediate post-operative period for untoward events including recurrence of neuromuscular blockade.</p><p><u>Monitoring respiratory function during recovery:</u></p><p>Ventilatory support is mandatory for patients until adequate spontaneous respiration is restored following reversal of neuromuscular blockade. Even if recovery from neuromuscular blockade is complete, other medicinal products used in the peri- and post-operative period could depress respiratory function and therefore ventilatory support might still be required.</p><p>Should neuromuscular blockade reoccur following extubation, adequate ventilation should be provided.</p><p><u>Recurrence of neuromuscular blockade:</u></p><p>In clinical studies with subjects treated with rocuronium or vecuronium, where sugammadex was administered using a dose labelled for the depth of neuromuscular blockade, an incidence of 0.20% was observed for recurrence of neuromuscular blockade as based on neuromuscular monitoring or clinical evidence. The use of lower than recommended doses may lead to an increased risk of recurrence of neuromuscular blockade after initial reversal and is not recommended.</p><p><u>Effect on haemostasis:</u></p><p>In a study in volunteers doses of 4 mg/kg and 16 mg/kg of sugammadex resulted in maximum mean prolongations of the activated partial thromboplastin time (aPTT) by 17 and 22% respectively and prothrombin time international normalized ratio [PT(INR)] by 11 and 22% respectively. These limited mean aPTT and PT(INR) prolongations were of short duration (&le; 30 minutes). Based on the clinical data-base (N=3,519) and on a specific study in 1184 patients undergoing hip fracture/major joint replacement surgery there was no clinically relevant effect of sugammadex 4 mg/kg alone or in combination with anticoagulants on the incidence of peri- or post-operative bleeding complications.</p><p>&nbsp;</p><p>In <em>in vitro </em>experiments a pharmacodynamic interaction (aPTT and PT prolongation) was noted with vitamin K antagonists, unfractionated heparin, low molecular weight heparinoids, rivaroxaban and dabigatran. In patients receiving routine post-operative prophylactic anticoagulation this pharmacodynamic interaction is not clinically relevant. Caution should be exercised when considering the use of sugammadex in patients receiving therapeutic anticoagulation for a pre-existing or co-morbid condition.</p><p>An increased risk of bleeding cannot be excluded in patients:</p><p>&bull;&nbsp; with hereditary vitamin K dependent clotting factor deficiencies;</p><p>&bull;&nbsp; with pre-existing coagulopathies;</p><p>&bull;&nbsp; on coumarin derivates and at an INR above 3.5;</p><p>&bull;&nbsp; using anticoagulants who receive a dose of 16 mg/kg sugammadex.</p><p>If there is a medical need to give sugammadex to these patients the anaesthesiologist needs to decide if the benefits outweigh the possible risk of bleeding complications taking into consideration the patients history of bleeding episodes and type of surgery scheduled. If sugammadex is administered to these patients monitoring of haemostasis and coagulation parameters is recommended.</p><p><u>Waiting times for re-administration with neuromuscular blocking agents after reversal with</u> <u>sugammadex:</u></p><p>Table 1: Re-administration of rocuronium or vecuronium after routine reversal (up to 4 mg/kg sugammadex):</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Minimum waiting time</strong></p></td><td style="vertical-align:top"><p><strong>NMBA and dose to be administered</strong></p></td></tr><tr><td style="vertical-align:top"><p>5 minutes</p></td><td style="vertical-align:top"><p>1.2 mg/kg rocuronium</p></td></tr><tr><td style="vertical-align:top"><p>4 hours</p></td><td style="vertical-align:top"><p>0.6 mg/kg rocuronium or</p><p>0.1 mg/kg vecuronium</p></td></tr></tbody></table><p>The onset of neuromuscular blockade may be prolonged up to approximately 4 minutes, and the duration of neuromuscular blockade may be shortened up to approximately 15 minutes after re- administration of rocuronium 1.2 mg/kg within 30 minutes after sugammadex administration.</p><p>Based on PK modelling the recommended waiting time in patients with mild or moderate renal impairment for re-use of 0.6 mg/kg rocuronium or 0.1 mg/kg vecuronium after routine reversal with sugammadex should be 24 hours. If a shorter waiting time is required, the rocuronium dose for a new neuromuscular blockade should be 1.2 mg/kg.</p><p>Re-administration of rocuronium or vecuronium after immediate reversal (16 mg/kg sugammadex):</p><p>For the very rare cases where this might be required, a waiting time of 24 hours is suggested.</p><p>If neuromuscular blockade is required before the recommended waiting time has passed, a <strong>nonsteroidal neuromuscular blocking agent </strong>should be used. The onset of a depolarizing neuromuscular blocking agent might be slower than expected, because a substantial fraction of postjunctional nicotinic receptors can still be occupied by the neuromuscular blocking agent.</p><p><u>Renal impairment:</u></p><p>Sugammadex is not recommended for use in patients with severe renal impairment, including those requiring dialysis.</p><p><u>Light anaesthesia:</u></p><p>&nbsp;</p><p>When neuromuscular blockade was reversed intentionally in the middle of anaesthesia in clinical trials, signs of light anaesthesia were noted occasionally (movement, coughing, grimacing and suckling of the tracheal tube).</p><p>If neuromuscular blockade is reversed, while anaesthesia is continued, additional doses of anaesthetic and/or opioid should be given as clinically indicated.</p><p><u>Marked bradycardia:</u></p><p>In rare instances, marked bradycardia has been observed within minutes after the administration of sugammadex for reversal of neuromuscular blockade. Bradycardia may occasionally lead to cardiac arrest. Patients should be closely monitored for hemodynamic changes during and after reversal of neuromuscular blockade. Treatment with anti-cholinergic agents such as atropine should be administered if clinically significant bradycardia is observed.</p><p><u>Hepatic impairment:</u></p><p>Sugammadex is not metabolised nor excreted by the liver; therefore dedicated studies in patients with hepatic impairment have not been conducted. Patients with severe hepatic impairment should be treated with great caution. In case hepatic impairment is accompanied by coagulopathy see the information on the effect on haemostasis.</p><p><u>Use in Intensive Care Unit (ICU):</u></p><p>Sugammadex has not been investigated in patients receiving rocuronium or vecuronium in the ICU setting.</p><p><u>Use for reversal of neuromuscular blocking agents other than rocuronium or vecuronium:</u></p><p>Sugammadex should not be used to reverse block induced by <strong>nonsteroidal </strong>neuromuscular blocking agents such as succinylcholine or benzylisoquinolinium compounds.</p><p>Sugammadex&nbsp; should&nbsp; not&nbsp; be&nbsp; used&nbsp; for&nbsp; reversal&nbsp; of&nbsp; neuromuscular&nbsp; blockade&nbsp; induced by <strong>steroidal </strong>neuromuscular blocking agents other than rocuronium or vecuronium, since there are no efficacy and safety data for these situations. Limited data are available for reversal of pancuronium induced blockade, but it is advised not to use sugammadex in this situation.</p><p><u>Delayed recovery:</u></p><p>Conditions associated with prolonged circulation time such as cardiovascular disease, old age (see section 4.2 the time to recovery in elderly), or oedematous state (e.g., severe hepatic impairment) may be associated with longer recovery times.</p><p><u>Drug hypersensitivity reactions:</u></p><p>Clinicians should be prepared for the possibility of drug hypersensitivity reactions (including anaphylactic reactions) and take the necessary <u>precautions</u>.</p><p><u>Sodium:</u></p><p>This medicinal product contains up to 9.7 mg sodium per mL, equivalent to 0.5 % of the WHO recommended maximum daily intake of 2 g sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The information in this section is based on binding affinity between sugammadex and other medicinal products, non-clinical experiments, clinical studies and simulations using a model taking into account the pharmacodynamic effect of neuromuscular blocking agents and the pharmacokinetic interaction between neuromuscular blocking agents and sugammadex. Based on these data, no clinically significant pharmacodynamic interaction with other medicinal products is expected, with exception of the following:</p><p>For toremifene and fusidic acid displacement interactions could not be excluded (no clinically relevant capturing interactions are expected).</p><p>For hormonal contraceptives a clinically relevant capturing interaction could not be excluded (no displacement interactions are expected).</p><p><u>Interactions potentially affecting the efficacy of sugammadex (displacement interactions):</u></p><p>Due to the administration of certain medicinal products after sugammadex, theoretically rocuronium or vecuronium could be displaced from sugammadex. As a result recurrence of neuromuscular blockade might be observed. In this situation the patient must be ventilated. Administration of the medicinal product which caused displacement should be stopped in case of an infusion. In situations when potential displacement interactions can be anticipated, patients should be carefully monitored for signs of recurrence of neuromuscular blockade (approximately up to 15 minutes) after parenteral administration of another medicinal product occurring within a period of 7.5 hours after sugammadex administration.</p><p>Toremifene:</p><p>For toremifene, which has a relatively high binding affinity for sugammadex and for which relatively high plasma concentrations might be present, some displacement of vecuronium or rocuronium from the complex with sugammadex could occur. Clinicians should be aware that the recovery of the T4/T1 ratio to 0.9 could therefore be delayed in patients who have received toremifene on the same day of the operation.</p><p>Intravenous administration of fusidic acid:</p><p>The use of fusidic acid in the pre-operative phase may give some delay in the recovery of the T4/T1 ratio to 0.9. No recurrence of neuromuscular blockade is expected in the post-operative phase, since the infusion rate of fusidic acid is over a period of several hours and the blood levels are cumulative over 2-3 days. For re-administration of sugammadex.</p><p><u>Interactions potentially affecting the efficacy of other medicinal products (capturing interactions):</u></p><p>Due to the administration of sugammadex, certain medicinal products could become less effective due to a lowering of the (free) plasma concentrations. If such a situation is observed, the clinician is advised to consider the re-administration of the medicinal product, the administration of a therapeutically equivalent medicinal product (preferably from a different chemical class) and/or non-pharmacological interventions as appropriate.</p><p>Hormonal contraceptives:</p><p>The interaction between 4 mg/kg sugammadex and a progestogen was predicted to lead to a decrease in progestogen exposure (34% of AUC) similar to the decrease seen when a daily dose of an oral contraceptive is taken 12 hours too late, which might lead to a reduction in effectiveness. For oestrogens, the effect is expected to be lower. Therefore the administration of a bolus dose of sugammadex is considered to be equivalent to one missed daily dose of <strong>oral </strong>contraceptive steroids (either combined or progestogen only). If sugammadex is administered at the same day as an oral contraceptive is taken reference is made to missed dose advice in the package leaflet of the oral contraceptive. In the case of <strong>non-oral </strong>hormonal contraceptives, the patient must use an additional non hormonal contraceptive method for the next 7 days and refer to the advice in the package leaflet of the product.</p><p><u>Interactions due to the lasting effect of rocuronium or vecuronium:</u></p><p>&nbsp;</p><p>When medicinal products which potentiate neuromuscular blockade are used in the post-operative period special attention should be paid to the possibility of recurrence of neuromuscular blockade. Please refer to the package leaflet of rocuronium or vecuronium for a list of the specific medicinal products which potentiate neuromuscular blockade. In case recurrence of neuromuscular blockade is observed, the patient may require mechanical ventilation and re-administration of sugammadex.</p><p><u>Interference with laboratory tests:</u></p><p>In general sugammadex does not interfere with laboratory tests, with the possible exception of the serum progesterone assay. Interference with this test is observed at sugammadex plasma concentrations of 100 microgram/mL (peak plasma level following 8 mg/kg bolus injection).</p><p>In a study in volunteers doses of 4 mg/kg and 16 mg/kg of sugammadex resulted in maximum mean prolongations of aPTT by 17 and 22% respectively and of PT(INR) by 11 and 22% respectively. These limited mean aPTT and PT(INR) prolongations were of short duration (&le; 30 minutes).</p><p>In <em>in vitro </em>experiments a pharmacodynamic interaction (aPTT and PT prolongation) was noted with vitamin K antagonists, unfractionated heparin, low molecular weight heparinoids, rivaroxaban and Dabigatran.</p><p><u>Paediatric population</u></p><p>No formal interaction studies have been performed. The above mentioned interactions for adults and the warnings in section 4.4 should also be taken into account for the paediatric population.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>For sugammadex no clinical data on exposed pregnancies are available.</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonic/foetal development, parturition or postnatal development.</p><p>Caution should be exercised when administering sugammadex to pregnant women. <u>Breast-feeding</u></p><p>It is unknown whether sugammadex is excreted in human breast milk. Animal studies have shown excretion of sugammadex in breast milk. Oral absorption of cyclodextrins in general is low and no effect on the suckling child is anticipated following a single dose to the breast-feeding woman.</p><p>A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from sugammadex therapy, taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.</p><p><u>Fertility</u></p><p>The effects with sugammadex on human fertility have not been investigated. Animal studies to evaluate fertility do not reveal harmful effects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sugammadex has no known influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>Sugammadex is administered concomitantly with neuromuscular blocking agents and anaesthetics in surgical patients. The causality of adverse events is therefore difficult to assess.</p><p>&nbsp;</p><p>The most commonly reported adverse reactions in surgical patients were cough, airway complication of anaesthesia, anaesthetic complications, procedural hypotension and procedural complication (Common (&ge; 1/100 to &lt; 1/10)).</p><p>Table 2: Tabulated list of adverse reactions</p><p>The safety of sugammadex has been evaluated in 3,519 unique subjects across a pooled phase I- III safety database. The following adverse reactions were reported in placebo controlled trials where subjects received anaesthesia and/or neuromuscular blocking agents (1,078 subject exposures to sugammadex versus 544 to placebo):</p><p><em>[Very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000)]</em></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequencies</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions (Preferred terms)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Drug&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypersensitivity reactions</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td style="vertical-align:top"><p>Injury,&nbsp;&nbsp;&nbsp;&nbsp; poisoning&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and procedural complications</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Airway&nbsp;&nbsp;&nbsp; complication&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of anaesthesia</p><p>Anaesthetic&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; complication Procedural hypotension Procedural complication</p></td></tr></tbody></table><p><u>Description of selected adverse reactions</u> Drug hypersensitivity reactions:</p><p>Hypersensitivity reactions, including anaphylaxis, have occurred in some patients and volunteers (for information on volunteers, see Information on healthy volunteers below). In clinical trials of surgical patients these reactions were reported uncommonly and for post-marketing reports the frequency is unknown.</p><p>These reactions varied from isolated skin reactions to serious systemic reactions (i.e. anaphylaxis, anaphylactic shock) and have occurred in patients with no prior exposure to sugammadex.</p><p>Symptoms associated with these reactions can include: flushing, urticaria, erythematous rash, (severe) hypotension, tachycardia, swelling of tongue, swelling of pharynx, bronchospasm and pulmonary obstructive events. Severe hypersensitivity reactions can be fatal.</p><p>Airway complication of anaesthesia:</p><p>Airway complications of anaesthesia included bucking against the endotracheal tube, coughing, mild bucking, arousal reaction during surgery, coughing during the anaesthetic procedure or during surgery, or anaesthetic procedure-related spontaneous breath of patient.</p><p>Anaesthetic complication:</p><p>Anaesthetic complications, indicative of the restoration of neuromuscular function, include movement of a limb or the body or coughing during the anaesthetic procedure or during surgery, grimacing, or suckling on the endotracheal tube.</p><p>Procedural complication:</p><p>Procedural complications included coughing, tachycardia, bradycardia, movement, and increase in heart rate.</p><p>Marked bradycardia:</p><p>&nbsp;</p><p>In post-marketing, isolated cases of marked bradycardia and bradycardia with cardiac arrest have been observed within minutes after administration of sugammadex.</p><p>Recurrence of neuromuscular blockade:</p><p>In clinical studies with subjects treated with rocuronium or vecuronium, where sugammadex was administered using a dose labelled for the depth of neuromuscular blockade (N=2,022), an incidence of 0.20% was observed for recurrence of neuromuscular blockade as based on neuromuscular monitoring or clinical evidence.</p><p>Information on healthy volunteers:</p><p>A randomised, double-blind study examined the incidence of drug hypersensitivity reactions in healthy volunteers given up to 3 doses of placebo (N=76), sugammadex 4 mg/kg (N=151) or sugammadex 16 mg/kg (N=148). Reports of suspected hypersensitivity were adjudicated by a blinded committee. The incidence of adjudicated hypersensitivity was 1.3%, 6.6% and 9.5% in the placebo, sugammadex 4 mg/kg and sugammadex 16 mg/kg groups, respectively. There were no reports of anaphylaxis after placebo or sugammadex 4 mg/kg. There was a single case of adjudicated anaphylaxis after the first dose of sugammadex 16 mg/kg (incidence 0.7%). There was no evidence of increased frequency or severity of hypersensitivity with repeat dosing of sugammadex.</p><p>In a previous study of similar design, there were three adjudicated cases of anaphylaxis, all after sugammadex 16 mg/kg (incidence 2.0%).</p><p>In the Pooled Phase 1 database, AEs considered common (&ge; 1/100 to &lt; 1/10) or very common (&ge; 1/10) and more frequent among subjects treated with sugammadex than in the placebo group, include dysgeusia (10.1%), headache (6.7%), nausea (5.6%), urticaria (1.7%), pruritus (1.7%), dizziness (1.6%), vomiting (1.2%) and abdominal pain (1.0%).</p><p><em>Additional information on special populations</em></p><p>Pulmonary patients:</p><p>In post-marketing data and in one dedicated clinical trial in patients with a history of pulmonary complications, bronchospasm was reported as a possibly related adverse event. As with all patients with a history of pulmonary complications the physician should be aware of the possible occurrence of bronchospasm.</p><p><em>Paediatric population</em></p><p>In studies of paediatric patients 2 to 17 years of age, the safety profile of sugammadex (up to 4 mg/kg) was generally similar to the profile observed in adults.</p><p><em>Morbidly obese patients</em></p><p>In one dedicated clinical trial in morbidly obese patients, the safety profile was generally similar to the profile in adult patients in pooled Phase 1 to 3 studies (see Table 2).</p><p>&nbsp;</p><p><em>Patients with severe systemic disease</em></p><p><em>&nbsp;</em></p><p>In a trial in patients who were assessed as American Society of Anesthesiologists (ASA) Class 3 or 4 (patients with severe systemic disease or patients with severe systemic disease that is a constant threat to life), the adverse reaction profile in these ASA Class 3 and 4 patients was generally similar to that of adult patients in pooled Phase 1 to 3 studies (see Table 2).</p><p>&nbsp;</p><p><u>To reports any side effect(s):</u></p><p>&nbsp;</p><p><strong>Saudi Arabia:</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Textbox_x0020_1" o:spid="_x0000_s1027" type="#_x0000_t202"
  style='position:absolute;margin-left:92.9pt;margin-top:14.6pt;width:453.25pt;
  height:73.35pt;z-index:-15728640;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokeweight="1.44pt">
  <v:path arrowok="t"/>
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText align=left style='margin-top:1.0pt;margin-right:0in;
     margin-bottom:0in;margin-left:23.35pt;margin-bottom:.0001pt;text-align:
     left;text-indent:-.25in;mso-list:l0 level1 lfo2;tab-stops:23.35pt'><![if !supportLists]><span
     style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
     Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span>The<span
     style='letter-spacing:-.2pt'> </span>National<span style='letter-spacing:
     -.1pt'> </span>Pharmacovigilance<span style='letter-spacing:-.15pt'> </span>Centre<span
     style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>(NPC):</span><o:p></o:p></p>
     <p class=MsoBodyText align=left style='margin-top:13.75pt;margin-right:
     0in;margin-bottom:0in;margin-left:23.35pt;margin-bottom:.0001pt;
     text-align:left;text-indent:-.25in;mso-list:l1 level1 lfo1;tab-stops:23.35pt'><![if !supportLists]><span
     style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span><![endif]><span dir=LTR></span>SFDA<span style='letter-spacing:
     -.2pt'> </span>Call<span style='letter-spacing:-.1pt'> </span>Center:<span
     style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.2pt'>19999</span><o:p></o:p></p>
     <p class=MsoBodyText align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:0in;margin-left:23.35pt;margin-bottom:.0001pt;text-align:
     left;text-indent:-.25in;mso-list:l1 level1 lfo1;tab-stops:23.35pt'><![if !supportLists]><span
     style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span><![endif]><span dir=LTR></span><span lang=FR
     style='mso-ansi-language:FR'>E-mail:<span style='letter-spacing:-.15pt'> </span></span><a
     href="mailto:npc.drug@sfda.gov.sa"><span lang=FR style='color:#0461C1;
     letter-spacing:-.1pt;mso-ansi-language:FR'>npc.drug@sfda.gov.sa</span></a><span
     lang=FR style='mso-ansi-language:FR'><o:p></o:p></span></p>
     <p class=MsoBodyText align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:0in;margin-left:23.35pt;margin-bottom:.0001pt;text-align:
     left;text-indent:-.25in;mso-list:l1 level1 lfo1;tab-stops:23.35pt'><![if !supportLists]><span
     style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span><![endif]><span dir=LTR></span>Website:<span
     style='letter-spacing:-.15pt'> </span><u style='text-underline:#0461C1'><span
     style='color:#0461C1;letter-spacing:-.1pt'>https://ade.sfda.gov.sa/</span></u><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left" style="width:838.788px"><tbody><tr><td style="width:1px">&nbsp;</td></tr><tr><td style="width:1px">&nbsp;</td><td style="width:837.212px"><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: <u>https://ade.sfda.gov.sa/</u></p></td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Other GCC States:</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="Textbox_x0020_2" o:spid="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:92.9pt;margin-top:14.7pt;width:453.25pt;height:17.2pt;z-index:-15728128;
  visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAm6VJw0ADAADeEgAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsWNtu2zAMfd6A/YOg9zSOlzvqFGu7
DgOKNkjaD2AUOTYmS5qk3Pr1o2Q7DTKsQ7vtJUuCOJRJUeQhRZs6v9gUgqy4sbmSCW2dRZRwydQ8
l4uEPj7cNPqUWAdyDkJJntAtt/Ri9OH9OQwXBnSWM4IapB1CQjPn9LDZtCzjBdgzpblEXqpMAQ6H
ZtGcG1ij5kI04yjqNgvIJR09q7oGB2Rp8jeoEop94/MrkCuwqFKw4f6dykbB/lwzDOXqi9FTPTbe
cna3GhuSzxOKyEkoECLarBiVGA6bB7MWzwo2qSm8vEpTssEItHqD1qBDyTah8WDQjuJOqY9vHGEo
0Ol1unEPBZiXaPXb7ahaMLv/jQqWfX5ZCZpZmoPEnolWewPl6mef49rnBzRvpjYk3jnvhYnbXCrv
VAiy1bcYJFvCgbiV6gI0tWZbofqXQNn5A0NtrPvCVUE8kVDDmQtGwerWutKkWsQ7KyRZo939uN8v
bVcin9/kQnimNYvZlTBkBQLDHj7ebVzN7ot5fddgs1IusCoxIUvpylu3mQaEPVrzrV9hhv8IH+5L
d4+XVCi0holcU5Ip83R4b407MaH2+xIMp0R8lTako6sJUxOzmjBOXClvffBOqk9Lp9K8AqJcPcBg
3dRtBUfvEMJwQbMKMLcJ7fYGbUxDHEzCaiAWWEFEFWp2yVMvbzUbO1tCMAiZ6mHSNdvBDPH3gkgR
rdDweNDteMW1vhLZWhBnV6gZP8ugOQJ8reKy8TjFWvWEYcPigpTG3d7olB7yNMWIl6HG6ILLJXFb
zVNguGMf8oJbcsfXZKIKkJRokMoiI4rx240+Rp2ojb8YqTZyc8eyGyhygVuwhQWSZWAsx7SqtiKH
f6Yc/UefA2Cjhk85BM/fC2C8jIjnHiUO78aCg+WvQ6PKj1YnJOxR4kJeh8jR5gdT0gFzr0Ojzo8j
rh+n/PAp70Yue1vtOJWO+mF7tKXDcMFXIE+1o3pz3b17nGpHWTuYKjR3/I0ZcqogdQX5Dx63sHTY
vOVue3bwJsLlfAwGJr/sZY6tvD47HJoXbCx9I7PrfpeWT/UE+7Wq9QvtMUr4c4jmwclOmFqdRPnj
o/3x6AcAAAD//wMAUEsDBBQABgAIAAAAIQDhUTcfzwYAAOYbAAAaAAAAY2xpcGJvYXJkL3RoZW1l
L3RoZW1lMS54bWzsWc1v3EQUvyPxP4x8b7PfzUbdVNnNbgNt2ijZFvU4a8/a04w91sxs0r2h9oiE
hCiIA5W4cUBApVbiUv6aQBEUqf8Cb2ZsryfrkLSNoILmkLWff/O+35uvy1fuxQwdECEpT3pe/WLN
QyTxeUCTsOfdGo8urHpIKpwEmPGE9Lw5kd6V9fffu4zXfEbTCcciGEckJggYJXIN97xIqXRtZUX6
QMbyIk9JAt+mXMRYwasIVwKBD0FAzFYatVpnJcY08daBo9KMhgz+JUpqgs/EnmZDUIJjkH5zOqU+
Mdhgv64Rci4HTKADzHoe8Az44ZjcUx5iWCr40PNq5s9bWb+8gteyQUydMLY0bmT+snHZgGC/YWSK
cFIIrY9a3UubBX8DYGoZNxwOB8N6wc8AsO+DpVaXMs/WaLXez3mWQPZxmfeg1q61XHyJf3NJ526/
3293M10sUwOyj60l/Gqt09poOHgDsvj2Er7V3xgMOg7egCy+s4QfXep2Wi7egCJGk/0ltA7oaJRx
LyBTzrYq4asAX61l8AUKsqHILi1iyhN1Uq7F+C4XIwBoIMOKJkjNUzLFPuTkAMcTQbEWgNcILn2x
JF8ukbQsJH1BU9XzPkxx4pUgL599//LZE3R0/+nR/Z+OHjw4uv+jZeSM2sJJWB714tvP/nz0Mfrj
yTcvHn5RjZdl/K8/fPLLz59XA6F8FuY9//Lxb08fP//q09+/e1gB3xB4UoaPaUwkukEO0S6PwTDj
FVdzMhGvNmIcYVoesZGEEidYS6ngP1SRg74xxyyLjqNHn7gevC2gfVQBr87uOgrvRWKmaIXka1Hs
ALc5Z30uKr1wTcsquXk8S8Jq4WJWxu1ifFAle4ATJ77DWQp9M09Lx/BBRBw1dxhOFA5JQhTS3/g+
IRXW3aHU8es29QWXfKrQHYr6mFa6ZEwnTjYtBm3RGOIyr7IZ4u34Zvs26nNWZfUmOXCRUBWYVSg/
Jsxx41U8UziuYjnGMSs7/DpWUZWSe3Phl3FDqSDSIWEcDQMiZdWYmwLsLQX9GoaOVRn2bTaPXaRQ
dL+K53XMeRm5yfcHEY7TKuweTaIy9gO5DymK0Q5XVfBt7laIfoc44OTEcN+mxAn36d3gFg0dlRYJ
or/MhI4ltGqnA8c0+bt2zCj0Y5sD59eOoQE+//pRRWa9rY14A+akqkrYOtZ+T8Idb7oDLgL69vfc
TTxLdgik+fLE867lvmu53n++5Z5Uz2dttIveCm1XrxvsotgskeMTV8hTytiemjNyXZpFsoR5IhgB
UY8zO0FS7JjSCB6zvu7gQoHNGCS4+oiqaC/CKSyw655mEsqMdShRyiVs7Ay5krfGwyJd2W1hW28Y
bD+QWG3zwJKbmpzvCwo2ZrYJzeYzF9TUDM4qrHkpYwpmv46wulbqzNLqRjXT6hxphckQw2XTgFh4
ExYgCJYt4OUO7MW1aNiYYEYC7Xc79+ZhMVE4zxDJCAcki5G2ezlGdROkPFfMSQDkTkWM9CbvFK+V
pHU12zeQdpYglcW1ThCXR+9NopRn8CJKum6PlSNLysXJEnTY87rtRttDPk573hT2tPAYpxB1qdd8
mIVwGuQrYdP+1GI2Vb6IZjc3zC2COhxTWL8vGez0gVRItYllZFPDfMpSgCVaktW/0Qa3npcBNtNf
Q4vmKiTDv6YF+NENLZlOia/KwS5RtO/sa9ZK+UwRsRcFh2jCZmIXQ/h1qoI9AZVwNGE6gn6BczTt
bfPJbc5Z0ZVPrwzO0jFLI5y1W12ieSVbuKnjQgfzVlIPbKvU3Rj36qaYkj8nU8pp/D8zRc8ncFLQ
DHQEfDiUFRjpeu15XKiIQxdKI+qPBCwcTO+AbIGzWPgMSQUnyOZXkAP9a2vO8jBlDRs+tUtDJCjM
RyoShOxAWzLZdwqzejZ3WZYsY2QyqqSuTK3aE3JA2Fj3wI6e2z0UQaqbbpK1AYM7nn/ue1ZBk1Av
csr15vSQYu61NfBPr3xsMYNRbh82C5rc/4WKFbOqHW+G53Nv2RD9YbHMauVVAcJKU0E3K/vXVOEV
p1rbsZYsbrRz5SCKyxYDsVgQpXDeg/Q/mP+o8Jm9bdAT6pjvQm9FcNGgmUHaQFZfsAsPpBukJU5g
4WSJNpk0K+vabOmkvZZP1ue80i3kHnO21uws8X5FZxeLM1ecU4vn6ezMw46vLe1EV0Nkj5cokKb5
RsYEpurWaRunaBLWex7c/ECg78ET3B15QGtoWkPT4AkuhGCxZG9xel72kFPgu6UUmGZOaeaYVk5p
5ZR2ToHFWXZfklM60Kn0FQdcsekfD+W3GbCCy24/8qbqXM2t/wUAAP//AwBQSwMEFAAGAAgAAAAh
AJxmRkG7AAAAJAEAACoAAABjbGlwYm9hcmQvZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEueG1sLnJl
bHOEj80KwjAQhO+C7xD2btJ6EJEmvYjQq9QHCMk2LTY/JFHs2xvoRUHwsjCz7DezTfuyM3liTJN3
HGpaAUGnvJ6c4XDrL7sjkJSl03L2DjksmKAV201zxVnmcpTGKSRSKC5xGHMOJ8aSGtHKRH1AVzaD
j1bmIqNhQaq7NMj2VXVg8ZMB4otJOs0hdroG0i+hJP9n+2GYFJ69elh0+UcEy6UXFqCMBjMHSldn
nTUtXYGJhn39Jt4AAAD//wMAUEsBAi0AFAAGAAgAAAAhALvlSJQFAQAAHgIAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEArTA/8cEAAAAyAQAACwAA
AAAAAAAAAAAAAAA2AQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAm6VJw0ADAADeEgAAHwAA
AAAAAAAAAAAAAAAgAgAAY2xpcGJvYXJkL2RyYXdpbmdzL2RyYXdpbmcxLnhtbFBLAQItABQABgAI
AAAAIQDhUTcfzwYAAOYbAAAaAAAAAAAAAAAAAAAAAJ0FAABjbGlwYm9hcmQvdGhlbWUvdGhlbWUx
LnhtbFBLAQItABQABgAIAAAAIQCcZkZBuwAAACQBAAAqAAAAAAAAAAAAAAAAAKQMAABjbGlwYm9h
cmQvZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEueG1sLnJlbHNQSwUGAAAAAAUABQBnAQAApw0AAAAA
" filled="f" strokeweight="1.44pt">
  <v:path arrowok="t"/>
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText align=left style='margin-top:.9pt;margin-right:0in;
     margin-bottom:0in;margin-left:5.35pt;margin-bottom:.0001pt;text-align:
     left;tab-stops:23.35pt'><span style='letter-spacing:-.5pt'>-</span><span
     style='mso-tab-count:1'>     </span>Please<span style='letter-spacing:
     -.15pt'> </span>contact<span style='letter-spacing:-.1pt'> </span>the<span
     style='letter-spacing:-.05pt'> </span>relevant<span style='letter-spacing:
     -.1pt'> </span>competent<span style='letter-spacing:-.05pt'> </span><span
     style='letter-spacing:-.1pt'>authority.</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>-&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical studies, 1 case of an accidental overdose with 40 mg/kg was reported without any significant adverse reactions. In a human tolerance study sugammadex was administered in doses up to 96 mg/kg. No dose related adverse events nor serious adverse events were reported.</p><p>Sugammadex can be removed using haemodialysis with a high flux filter, but not with a low flux filter. Based upon clinical studies, sugammadex concentrations in plasma are reduced by up to 70% after a 3 to 6-hour dialysis session.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: all other therapeutic products, antidotes, ATC code: V03AB35 <u>Mechanism of action:</u></p><p>Sugammadex is a modified gamma cyclodextrin which is a Selective Relaxant Binding Agent. It forms a complex with the neuromuscular blocking agents rocuronium or vecuronium in plasma and thereby reduces the amount of neuromuscular blocking agent available to bind to nicotinic receptors in the neuromuscular junction. This results in the reversal of neuromuscular blockade induced by rocuronium or vecuronium.</p><p><u>Pharmacodynamic effects:</u></p><p>Sugammadex has been administered in doses ranging from 0.5 mg/kg to 16 mg/kg in dose response studies of rocuronium induced blockade (0.6, 0.9, 1.0 and 1.2 mg/kg rocuronium bromide with and without maintenance doses) and vecuronium induced blockade (0.1 mg/kg vecuronium bromide with or without maintenance doses) at different time points/depths of blockade. In these studies a clear dose-response relationship was observed.</p><p><u>Clinical efficacy and safety:</u></p><p>Sugammadex can be administered at several time points after administration of rocuronium or vecuronium bromide:</p><p><em>Routine reversal &ndash; deep neuromuscular blockade:</em></p><p>In a pivotal study patients were randomly assigned to the rocuronium or vecuronium group. After the last dose of rocuronium or vecuronium, at 1-2 PTCs, 4 mg/kg sugammadex or 70 mcg/kg neostigmine was administered in a randomised order. The time from start of administration of sugammadex or neostigmine to recovery of the T4/T1 ratio to 0.9 was:</p><p>Table 3: Time (minutes) from administration of sugammadex or neostigmine at deep neuromuscular blockade (1-2 PTCs) after rocuronium or vecuronium to recovery of the T4/T1 ratio to 0.9</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Neuromuscular</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blocking agent</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Treatment regimen</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Sugammadex (4 mg/kg)</strong></p></td><td style="vertical-align:top"><p><strong>Neostigmine (70 mcg/kg)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rocuronium</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>37</p></td><td style="vertical-align:top"><p>37</p></td></tr><tr><td style="vertical-align:top"><p>Median (minutes)</p></td><td style="vertical-align:top"><p>2.7</p></td><td style="vertical-align:top"><p>49.0</p></td></tr><tr><td style="vertical-align:top"><p>Range</p></td><td style="vertical-align:top"><p>1.2-16.1</p></td><td style="vertical-align:top"><p>13.3-145.7</p></td></tr><tr><td style="vertical-align:top"><p>Vecuronium</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>47</p></td><td style="vertical-align:top"><p>36</p></td></tr><tr><td style="vertical-align:top"><p>Median (minutes)</p></td><td style="vertical-align:top"><p>3.3</p></td><td style="vertical-align:top"><p>49.9</p></td></tr><tr><td style="vertical-align:top"><p>Range</p></td><td style="vertical-align:top"><p>1.4-68.4</p></td><td style="vertical-align:top"><p>46.0-312.7</p></td></tr></tbody></table><p><em>Routine reversal &ndash; moderate neuromuscular blockade:</em></p><p>In another pivotal study patients were randomly assigned to the rocuronium or vecuronium group. After the last dose of rocuronium or vecuronium, at the reappearance of T2, 2 mg/kg sugammadex or 50 mcg/kg neostigmine was administered in a randomised order. The time from start of administration of sugammadex or neostigmine to recovery of the T4/T1 ratio to 0.9 was:</p><p>Table 4: Time (minutes) from administration of sugammadex or neostigmine at reappearance of T2 after rocuronium or vecuronium to recovery of the T4/T1 ratio to 0.9</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Neuromuscular</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blocking agent</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Treatment regimen</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Sugammadex (2 mg/kg)</strong></p></td><td style="vertical-align:top"><p><strong>Neostigmine (50 mcg/kg)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rocuronium</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>48</p></td></tr><tr><td style="vertical-align:top"><p>Median (minutes)</p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top"><p>17.6</p></td></tr><tr><td style="vertical-align:top"><p>Range</p></td><td style="vertical-align:top"><p>0.9-5.4</p></td><td style="vertical-align:top"><p>3.7-106.9</p></td></tr><tr><td style="vertical-align:top"><p>Vecuronium</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>45</p></td></tr><tr><td style="vertical-align:top"><p>Median (minutes)</p></td><td style="vertical-align:top"><p>2.1</p></td><td style="vertical-align:top"><p>18.9</p></td></tr><tr><td style="vertical-align:top"><p>Range</p></td><td style="vertical-align:top"><p>1.2-64.2</p></td><td style="vertical-align:top"><p>2.9-76.2</p></td></tr></tbody></table><p>Reversal by sugammadex of the neuromuscular blockade induced by rocuronium was compared to the reversal by neostigmine of the neuromuscular blockade induced by cis-atracurium. At the reappearance of T2 a dose of 2 mg/kg sugammadex or 50 mcg/kg neostigmine was administered. Sugammadex provided faster reversal of neuromuscular blockade induced by rocuronium compared to neostigmine reversal of neuromuscular blockade induced by cis-atracurium:</p><p>Table 5: Time (minutes) from administration of sugammadex or neostigmine at reappearance of T2 after rocuronium or cis-atracurium to recovery of the T4/T1 ratio to 0.9</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Neuromuscular</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blocking agent</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Treatment regimen</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Rocuronium</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and sugammadex (2 mg/kg)</strong></p></td><td style="vertical-align:top"><p><strong>Cis-atracurium</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and neostigmine (50 mcg/kg)</strong></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>39</p></td></tr><tr><td style="vertical-align:top"><p>Median (minutes)</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>7.2</p></td></tr><tr><td style="vertical-align:top"><p>Range</p></td><td style="vertical-align:top"><p>0.7-6.4</p></td><td style="vertical-align:top"><p>4.2-28.2</p></td></tr></tbody></table><p><em>For immediate reversal:</em></p><p>&nbsp;</p><p>The time to recovery from succinylcholine-induced neuromuscular blockade (1 mg/kg) was compared with sugammadex (16 mg/kg, 3 minutes later) &ndash; induced recovery from rocuronium- induced neuromuscular blockade (1.2 mg/kg).</p><p>Table 6: Time (minutes) from administration of rocuronium and sugammadex or succinylcholine to recovery of the T1 10%</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Neuromuscular</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blocking agent</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Treatment regimen</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Rocuronium</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and sugammadex (16 mg/kg)</strong></p></td><td style="vertical-align:top"><p><strong>Succinylcholine (1 mg/kg)</strong></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>55</p></td><td style="vertical-align:top"><p>55</p></td></tr><tr><td style="vertical-align:top"><p>Median (minutes)</p></td><td style="vertical-align:top"><p>4.2</p></td><td style="vertical-align:top"><p>7.1</p></td></tr><tr><td style="vertical-align:top"><p>Range</p></td><td style="vertical-align:top"><p>3.5-7.7</p></td><td style="vertical-align:top"><p>3.7-10.5</p></td></tr></tbody></table><p>In a pooled analysis the following recovery times for 16 mg/kg sugammadex after 1.2 mg/kg rocuronium bromide were reported:</p><p>Table 7: Time (minutes) from administration of sugammadex at 3 minutes after rocuronium to recovery of the T4/T1 ratio to 0.9, 0.8 or 0.7</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>T</strong><strong>4</strong><strong>/T</strong><strong>1 </strong><strong>to 0.9</strong></p></td><td style="vertical-align:top"><p><strong>T</strong><strong>4</strong><strong>/T</strong><strong>1 </strong><strong>to 0.8</strong></p></td><td style="vertical-align:top"><p><strong>T</strong><strong>4</strong><strong>/T</strong><strong>1 </strong><strong>to 0.7</strong></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>65</p></td><td style="vertical-align:top"><p>65</p></td><td style="vertical-align:top"><p>65</p></td></tr><tr><td style="vertical-align:top"><p>Median (minutes)</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>1.3</p></td><td style="vertical-align:top"><p>1.1</p></td></tr><tr><td style="vertical-align:top"><p>Range</p></td><td style="vertical-align:top"><p>0.5-14.3</p></td><td style="vertical-align:top"><p>0.5-6.2</p></td><td style="vertical-align:top"><p>0.5-3.3</p></td></tr></tbody></table><p><em>Renal impairment:</em></p><p>Two open label studies compared the efficacy and safety of sugammadex in surgical patients with and without severe renal impairment. In one study, sugammadex was administered following rocuronium induced blockade at 1-2 PTCs (4 mg/kg; N=68); in the other study, sugammadex was administered at reappearance of T2 (2 mg/kg; N=30). Recovery from blockade was modestly longer for patients with severe renal impairment relative to patients without renal impairment. No residual neuromuscular blockade or recurrence of neuromuscular blockade was reported for patients with severe renal impairment in these studies.</p><p><em>Morbidly obese patients:</em></p><p>A trial of 188 patients who were diagnosed as morbidly obese investigated the time to recovery from moderate or deep neuromuscular blockade induced by rocuronium or vecuronium. Patients received 2 mg/kg or 4 mg/kg sugammadex, as appropriate for level of block, dosed according to either actual body weight or ideal body weight in random, double-blinded fashion. Pooled across depth of block and neuromuscular blocking agent, the median time to recover to a train-of-four (TOF) ratio &ge; 0.9 in patients dosed by actual body weight (1.8 minutes) was statistically significantly faster (p &lt; 0.0001) compared to patients dosed by ideal body weight (3.3 minutes).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The sugammadex pharmacokinetic parameters were calculated from the total sum of non-complex- bound and complex-bound concentrations of sugammadex. Pharmacokinetic parameters as clearance and volume of distribution are assumed to be the same for non-complex-bound and complex-bound sugammadex in anaesthetised subjects.</p><p><u>Distribution:</u></p><p>The observed steady-state volume of distribution of sugammadex is approximately 11 to 14 litres in adult patients with normal renal function (based on conventional, non-compartmental pharmacokinetic analysis). Neither sugammadex nor the complex of sugammadex and rocuronium binds to plasma proteins or erythrocytes, as was shown in vitro using male human plasma and</p><p>&nbsp;</p><p>whole blood. Sugammadex exhibits linear kinetics in the dosage range of 1 to 16 mg/kg when administered as an IV bolus dose.</p><p><u>Metabolism:</u></p><p>In preclinical and clinical studies no metabolites of sugammadex have been observed and only renal excretion of the unchanged product was observed as the route of elimination.</p><p><u>Elimination:</u></p><p>In adult anaesthetized patients with normal renal function the elimination half-life (t1/2) of sugammadex is about 2 hours and the estimated plasma clearance is about 88 mL/min. A mass balance study demonstrated that &gt; 90% of the dose was excreted within 24 hours. 96% of the dose was excreted in urine, of which at least 95% could be attributed to unchanged sugammadex. Excretion via faeces or expired air was less than 0.02% of the dose. Administration of sugammadex to healthy volunteers resulted in increased renal elimination of rocuronium in complex.</p><p><em>Special populations:</em></p><p><u>Renal impairment and age:</u></p><p>In a pharmacokinetic study comparing patients with severe renal impairment to patients with normal renal function, sugammadex levels in plasma were similar during the first hour after dosing, and thereafter the levels decreased faster in the control group. Total exposure to sugammadex was prolonged, leading to 17-fold higher exposure in patients with severe renal impairment. Low concentrations of sugammadex are detectable for at least 48 hours post-dose in patients with severe renal insufficiency.</p><p>In a second study comparing subjects with moderate or severe renal impairment to subjects with normal renal function, sugammadex clearance progressively decreased and t1/2 was progressively prolonged with declining renal function. Exposure was 2-fold and 5-fold higher in subjects with moderate and severe renal impairment, respectively. Sugammadex concentrations were no longer detectable beyond 7 days post-dose in subjects with severe renal insufficiency.</p><p>Table 8: A summary of sugammadex pharmacokinetic parameters stratified by age and renal function is presented below:</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Selected patient characteristics</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Mean Predicted PK parameters (CV%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Demographics</p></td><td colspan="3" style="vertical-align:top"><p>Renal function</p><p>Creatinine&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; clearance (mL/min)</p></td><td style="vertical-align:top"><p>Clearance (mL/min)</p></td><td style="vertical-align:top"><p>Volume&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of distribution at</p><p>steady state (L)</p></td><td style="vertical-align:top"><p>Elimination half- life (hr)</p></td></tr><tr><td style="vertical-align:top"><p>Adult</p></td><td style="vertical-align:top"><p>Normal</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>88 (22)</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>2 (21)</p></td></tr><tr><td style="vertical-align:top"><p>40 yrs</p></td><td style="vertical-align:top"><p>Impaired</p></td><td style="vertical-align:top"><p>Mild</p></td><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>51 (22)</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>4 (22)</p></td></tr><tr><td style="vertical-align:top"><p>75 kg</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Moderate</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>31 (23)</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>6 (23)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Severe</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>9 (22)</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>19 (24)</p></td></tr><tr><td style="vertical-align:top"><p>Elderly</p></td><td style="vertical-align:top"><p>Normal</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>75 (23)</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>2 (21)</p></td></tr><tr><td style="vertical-align:top"><p>75 yrs</p></td><td style="vertical-align:top"><p>Impaired</p></td><td style="vertical-align:top"><p>Mild</p></td><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>51 (24)</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>3 (22)</p></td></tr><tr><td style="vertical-align:top"><p>75 kg</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Moderate</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>31 (23)</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>6 (23)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Severe</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>9 (22)</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>19 (23)</p></td></tr><tr><td style="vertical-align:top"><p>Adolescent</p></td><td style="vertical-align:top"><p>Normal</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>95</p></td><td style="vertical-align:top"><p>77 (23)</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>2 (22)</p></td></tr><tr><td style="vertical-align:top"><p>15 yrs</p></td><td style="vertical-align:top"><p>Impaired</p></td><td style="vertical-align:top"><p>Mild</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>44 (23)</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>3 (22)</p></td></tr><tr><td style="vertical-align:top"><p>56 kg</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Moderate</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>27 (22)</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>5 (23)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Severe</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>8 (21)</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>17 (23)</p></td></tr><tr><td style="vertical-align:top"><p>Child</p></td><td style="vertical-align:top"><p>Normal</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>51</p></td><td style="vertical-align:top"><p>37 (22)</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>2 (20)</p></td></tr><tr><td style="vertical-align:top"><p>7 yrs</p></td><td style="vertical-align:top"><p>Impaired</p></td><td style="vertical-align:top"><p>Mild</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>19 (22)</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>3 (22)</p></td></tr><tr><td style="vertical-align:top"><p>23 kg</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Moderate</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>11 (22)</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>5 (22)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Severe</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>3 (22)</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>20 (25)</p></td></tr></tbody></table><p>CV=coefficient of variation</p><p>&nbsp;</p><p><u>Gender:</u></p><p>No gender differences were observed. <u>Race:</u></p><p>In a study in healthy Japanese and Caucasian subjects no clinically relevant differences in pharmacokinetic parameters were observed. Limited data does not indicate differences in pharmacokinetic parameters in Black or African Americans.</p><p><u>Body weight:</u></p><p>Population pharmacokinetic analysis of adult and elderly patients showed no clinically relevant relationship of clearance and volume of distribution with body weight.</p><p><u>Obesity:</u></p><p>In one clinical study in morbidly obese patients, sugammadex 2 mg/kg and 4 mg/kg was dosed according to actual body weight (n=76) or ideal body weight (n=74). Sugammadex exposure increased in a dose-dependent, linear manner following administration according to actual body weight or ideal body weight. No clinically relevant differences in pharmacokinetic parameters were observed between morbidly obese patients and the general population.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity potential, and toxicity to reproduction, local tolerance or compatibility with blood.</p><p>Sugammadex is rapidly cleared in preclinical species, although residual sugammadex was observed in bone and teeth of juvenile rats. Preclinical studies in young adult and mature rats demonstrate that sugammadex does not adversely affect tooth colour or bone quality, bone structure, or bone metabolism. Sugammadex has no effects on fracture repair and remodelling of bone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hydrochloric acid</p><p>Sodium hydroxide</p><p>Water for injections</p><p>Nitrogen</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
After first opening and dilution chemical and physical in-use stability has been demonstrated for 48 hours at 2°C to 25°C.
From a microbiological point of view, the diluted product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store Above 30 &deg;C. Protect from light. When not protected from light, the vial should be used within 5 days</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sugammadex injection 200 mg/2 mL (100 mg/mL) is packed in 2 mL Type I tubular glass vial with rubber stopper and flip off seal.</p><p>Sugammadex injection 500 mg/5 mL (100 mg/mL) is packed in 5 mL Type I tubular glass vial with rubber stopper and flip off seal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sugammadex can be injected into the intravenous line of a running infusion with the following intravenous solutions: sodium chloride 9 mg/mL (0.9%), glucose 50 mg/mL (5%), sodium chloride 4.5 mg/mL (0.45%) and glucose 25 mg/mL (2.5%), Ringers lactate solution, Ringers solution, glucose 50 mg/mL (5%) in sodium chloride 9 mg/mL (0.9%).</p><p>The infusion line should be adequately flushed (e.g., with 0.9% sodium chloride) between administration of Sugammadex and other drugs.</p><p><u>Use in the paediatric population</u></p><p>For paediatric patients Sugammadex can be diluted using sodium chloride 9 mg/mL (0.9%) to a concentration of 10 mg/mL.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sudair Pharma Company (SPC)
King Fahad road, Building 911- The First Round Riyadh, Saudi Arabia
Tel: +966-11-4668193
Fax: +966-11-4668195
Email: info@sudairpharma.com
Mailing: P.O. Box 19047 Riyadh, Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10/2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>